No title
BackgroundImmune-related hepatitis (ir-hepatitis) ranks among the most frequent adverse events of immune checkpoint inhibitors (ICIs). Limited knowledge exists regarding the incidence, characteristics, and treatment of patients having an inadequate response to initial therapy with steroids. Characterizing ir-hepatitis phenotypes and treatment responses can provide valuable insights for guiding tre
